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Pathophysiological cardiac and renal interactions are termed cardiovascular-
renal disorder (CvRD). Cardiovascular disease/dysfunction secondary to kidney 
disease (CvRDK), is a leading cause of death in human chronic kidney disease (CKD) 
patients.  The presence and clinical impact of CvRDK in dogs with CKD is unknown. 
We hypothesized that echocardiographic measurements, and cardiac and renal 
biomarkers, will be altered in dogs with CKD and associated with survival.  Eleven 
dogs with CKD (n=6 IRIS stage 2, n=5 IRIS stage 3) and without primary cardiac 
disease, plus 12 healthy age-matched control dogs, were recruited to this prospective 
observational study.  Dogs underwent standard echocardiography, glomerular filtration 
rate (GFR) estimation by iohexol clearance, and measurement of plasma cardiac 
troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP), plasma and 
urinary cystatin B, and urinary clusterin and neutrophil gelatinase-associated lipocalin 
(NGAL). Values were compared between groups, and their association with all-cause 
mortality explored.  
 
    Dogs with CKD had significantly lower GFR and higher NT-proBNP, urinary 
cystatin B, clusterin, and NGAL, compared to controls (P<0.05).  Echocardiographic 
measurements were similar between dogs with CKD and controls.  Median follow-up 
time was 666 days, during which six dogs with CKD died. Risk of death was 
associated with increasing age, serum total protein, and normalized left ventricular 
posterior wall thickness (LVPWDN) and decreasing bodyweight and packed cell 
volume. Although baseline differences in echocardiographic measurements were not 
evident between dogs with moderate CKD and controls, the presence of CvRDK was 




   





By virtue of their roles in fluid balance, tissue perfusion, and blood pressure, 
the physiology of the heart and kidney are inextricably intertwined (Kingma et al., 
2017).  As a result, disease or dysfunction of one system may lead to disease or 
dysfunction of the other, which has been described as cardiorenal syndrome in 
humans (Ronco et al., 2008; Rangaswami et al., 2019).  In veterinary medicine, a 
similar syndrome, termed cardiovascular-renal disorders (CvRD), has been proposed 
(Pouchelon et al., 2015).  CvRD describes three different circumstances as follows: 
kidney disease/dysfunction that arises secondary to heart disease (CvRDH), 
cardiovascular disease/dysfunction that arises secondary to kidney disease (CvRDK) 
and disease/dysfunction of both cardiovascular and kidney systems due to either 
concurrent primary heart and kidney disease or other pathophysiological mechanisms 
affecting both systems (e.g. systemic inflammation, drug or other intoxication, etc.) 
(CvRDO) (Pouchelon et al., 2015). 
    
Development of cardiovascular disease as a result of chronic kidney disease 
(CKD) is a well-characterized and important disease mechanism in human patients 
(Ronco and Di Lullo, 2014).  Patients with CKD are at 3-30 times higher risk for 
development of heart disease, and the majority of patients with advanced CKD die 
from congestive heart failure, myocardial infarction or arrhythmias as opposed to 
kidney failure (Muntner et al., 2002; Granata et al., 2016).  Diagnosis of cardiorenal 
syndrome is challenging, as the mere coexistence of both heart and kidney disease is 
insufficient evidence of this syndrome.  With regards to cardiovascular disease that 
arises secondary to kidney disease, kidney disease must causally trigger the 




neurohormonal activation, inflammation, oxidative stress, and endothelial dysfunction 
(Herzog et al., 2011; Alhaj et al., 2013), all of which can result in left ventricular 
systolic or diastolic dysfunction, volume overload, pressure overload, and myocardial 
remodeling.  Important aspects to better understanding cardiorenal syndrome in 
patients with CKD include characterization of “normal” heart function at baseline, 
detecting longitudinal changes in function, and identifying patient and laboratory 
characteristics that influence outcome (Clementi et al., 2013; Pinheiro da Silva and 
Vaz da Silva, 2016).  Interest in CvRD in veterinary medicine is a relatively recent 
phenomenon, and CvRD is incompletely described and understood (Pouchelon et al., 
2015; Keller et al., 2016; Martinelli et al., 2016; Jung et al., 2018).  To the authors’ 
knowledge, CvRD and its association with survival in dogs with CKD has not been 
specifically investigated.  The primary objective of this study was to describe baseline 
cardiac measurements and kidney function using echocardiography, biochemical 
parameters and biomarkers in a cohort of dogs with moderate CKD (International 
Renal Interest Society (IRIS) disease stages 2 and 3) compared to age- and weight-
matched healthy dogs, and to explore the effect of these parameters on long term 
outcome. The secondary objective was to provide pilot data that could be used to 
perform a sample size calculation for a larger, more definitive future study; for this 
reason no a priori sample size calculation was performed. 
 
Materials and Methods 
The study was approved by the University of Pennsylvania animal use and 
care committee (Approval number, IACUC 805002; Approval date, 21 July, 2014), 
and informed owner consent was obtained.  Dogs presenting to the Ryan Veterinary 




diagnosis of CKD was made on the basis of at least two episodes, over at least 3 
months, of minimally-concentrated urine (urine specific gravity < 1.030) with stable 
azotemia in the absence of other causes of polyuria or polydipsia. Additional factors 
considered included identification of renal proteinuria or ultrasonographic changes 
consistent with CKD (e.g., loss of corticomedullary distinction, irregular contours, 
and decreased renal size). Based on IRIS staging guidelines, dogs were assigned to 
either IRIS stage 2 (serum creatinine concentration 1.4 – 2.0 mg/dL) or stage 3 (serum 
creatinine concentration 2.1 – 5.0 mg/dL) CKD.1  The exclusion criteria included non-
azotemic and advanced CKD (i.e. IRIS stages 1 and 4), hypothyroidism, bodyweight 
<10kg, detection of a heart murmur on auscultation, echocardiographic evidence of 
primary heart disease, specifically degenerative mitral valve disease or idiopathic 
dilated cardiomyopathy (Dukes-McEwan et al., 2003), presence of an active urine 
sediment, or recent glucocorticoid or diuretic therapy.  Therapy with amlodipine or an 
angiotensin converting enzyme inhibitor for control of systemic hypertension was 
permitted.  A second cohort of healthy age- and weight-matched controls was 
recruited concurrently, primarily from students and hospital employees.  
 
A medical history was taken, and physical examination, blood sampling, blood 
pressure measurement, measurement of glomerular filtration rate (GFR) and 
echocardiography were performed.  Systolic blood pressure was measured in a quiet 
area following a period of acclimation for 5-10 min (Acierno et al., 2018).  Dogs were 
placed in lateral recumbency, and systolic blood pressure measured using Doppler 
sphygmomanometry using the uppermost thoracic limb and an inflatable cuff closest 
 
1 See: IRIS International Renal Society. http://www.iris-kidney.com/pdf/003-5559.001-iris-website-




to 40% of the antebrachial circumference (Ultrasonic Doppler Flow Detector, Parks 
Medical). The first measurement was discarded and the mean of 5-7 consecutive 
consistent measurements recorded.  GFR was estimated by a reference laboratory 
(Michigan State University Veterinary Diagnostic Laboratory, Lansing, MI), using 
the plasma clearance of iohexol method, as previously described (Heiene et al., 2010).  
Blood samples were obtained via jugular or cephalic venipuncture at baseline and 2, 3 
and 4 h post-iohexol administration, with sample volumes of 5.5mL, 3 mL, 3mL and 
3mL, respectively, collected at each time point. At baseline, blood samples were 
divided between plain and K-EDTA and lithium heparin treated tubes. At the 2, 3 and 
4 h post-iohexol time points all blood was collected into plain tubes. Serum 
biochemistry and plasma cTnI were performed by the University of Pennsylvania 
clinical laboratory using samples collected at baseline.  K-EDTA samples were 
separated by centrifugation at 1000g for 15 min and an aliquot of the resultant plasma 
transported at ambient temperature to a reference laboratory (IDEXX Laboratories) 
for analysis of NT-proBNP concentration using a second generation ELISA assay that 
has been previously validated in dogs (Cardiopet Canine proBNP, IDEXX 
Laboratories; Cahill et al., 2015). A second aliquot of K-EDTA plasma was stored at -
80 °C for subsequent batched analysis of plasma symmetric dimethylarginine 
(SDMA) and cystatin B at a reference laboratory (IDEXX Laboratories).   
 
Urine samples were collected by cystocentesis.  Urine specific gravity (USG) 
was measured using refractometry immediately following sample collection.  Each 
sample was divided into two aliquots.  One aliquot underwent routine urinalysis and 
measurement of the urinary protein to creatinine ratio (UPC), performed by the 




centrifugation at 1000g for 15 min.  The supernatant was stored at -80 °C for 
subsequent batched analysis of urinary cystatin B, neutrophil gelatinase-associated 
lipocalin (NGAL), and clusterin at a reference laboratory (IDEXX Laboratories).  All 
blood and urine sample processing was completed within 2 h of collection. All 
biomarker analyses were performed in duplicate and the mean of the two 
measurements reported. 
 
Kidney biomarker assays for plasma SDMA, plasma and urinary cystatin B, 
and urinary NGAL and clusterin were performed as previously described (Nabity et 
al., 2015; Yerramilli et al., 2016). Echocardiographic examinations were performed 
either by a board-certified cardiologist or a cardiology resident-in-training under the 
direct supervision of a board-certified cardiologist.  Dogs were placed in right, then 
left, lateral recumbency on an ultrasound examination table. The echocardiographic 
examination was performed using an ultrasound unit equipped with 3-8 MHz and 1-5 
MHz phased array transducers and ECG monitoring (iE33, Phillips). Standard 
imaging planes were digitally stored.  
 
The left atrial to aortic root ratio (LA:Ao) was measured from the right 
parasternal short axis view (Haggstrom et al., 1994; Hansson et al., 2002).  Left 
ventricular internal dimension in systole (LVIDs), left ventricular internal dimension 
in diastole (LVIDd), interventricular septal thickness in diastole (IVSd), and left 
ventricular posterior wall thickness in diastole (LVPWd) were measured from 2D 
right parasternal short axis views. LVIDs was normalized for bodyweight (LVIDSN) 
using the following formula:  





LVIDd was normalized for bodyweight (LVIDDN) using the following 
formula:  
LVIDd/[bodyweight (kg)] 0.294 
 
LVPWd was normalized for bodyweight (LVPWDN) using the following 
formula:  
LVPWd/[bodyweight (kg)] 0.232 
 
IVSd was normalized for bodyweight (IVSDN) using the following formula:  
IVSd/[bodyweight (kg)] 0.241  (Cornell et al., 2004) 
 
Tissue Doppler imaging profiles were obtained of the lateral mitral annulus, as 
previously described (Dickson et al., 2017). 
 
Statistical methods 
Statistical analysis was performed using commercially available software 
(SPSS 23, IBM; GraphPad Prism 7.00, GraphPad Software).  P values < 0.05 were 
considered statistically significant.  Due to the small sample size, median (range) 
values were reported for continuous variables.  Comparisons of continuous variables 
between groups were performed using Kruskal-Wallis tests with Dunn’s post hoc tests 
for multiple comparisons. Correlation between variables was assessed using 
Spearman correlation coefficients.  Survival time of dogs with CKD was calculated 
from date of enrolment to death, euthanasia, or end of study follow up (November 




telephone interview. Dogs were censored if they were still alive, or if they had been 
lost to follow-up. Univariate Cox proportional hazards models were constructed to 
investigate whether selected variables were associated with survival. 
 
Results 
The study was performed between October 2014 and November 2017.  Eleven 
dogs with CKD, including five in IRIS stage 2 (four females and one male), and six in 
IRIS stage 3 (four females and two males), were recruited between October 2014 and 
May 2016 and included in the study. Cross-breeds were most frequently represented 
(n = 3), followed by two each of old English sheep dog and golden retriever, and one 
each of four other breeds. Twelve healthy control dogs, including seven males and 
five females, were recruited between November 2014 and July 2016. Cross-breeds 
were most frequently represented (n = 4), followed by one each of eight other breeds. 
A summary of the physical examination findings and routine biochemical testing is 
shown in Table 1. All dogs underwent indirect ophthalmic examination by a board-
certified internist as part of their complete physical examination. No retinal lesions 
consistent with hypertensive retinopathy were observed.  Eleven dogs had systolic 
blood pressure measurements >160 mmHg, including 3/12 dogs in the control group, 
4/5 dogs in the IRIS stage 2 group and 4/6 dogs in the IRIS stage 3 group. Three dogs 
in the IRIS stage 3 group were receiving medications. Two dogs were receiving an 
ACE inhibitor (systolic blood pressures were 130 and 146 mmHg; both dogs had 
previously been documented to be proteinuric), and one dog was receiving 
amlodipine (systolic blood pressure was 180 mmHg).  No dog in IRIS stage 2 had 
previously been diagnosed with systemic hypertension and none were receiving anti-





Summary statistics for GFR, biomarker, and echocardiographic data from the 
three groups are shown in Table 2. Plasma SDMA and cystatin B, and urinary cystatin 
B, NGAL, and clusterin were measured in samples that had been stored at -80°C for 
2-27 months.  GFR was significantly lower in dogs with IRIS stage 3 compared to 
healthy controls (P < 0.001) but did not differ between controls and IRIS stage 2, or 
IRIS stages 2 and 3 (P = 0.050 and 0.482, respectively).  An overall difference 
between groups was detected for SDMA (P < 0.0001), plasma NT-proBNP (P = 
0.001), urinary cystatin B/ creatinine ratio (P = 0.005), urinary clusterin/ creatinine 
ratio (P = 0.019) and urinary NGAL/ creatinine ratio (P < 0.001; Table 2).  NT-
proBNP was moderately correlated with GFR (rs = -0.610; P = 0.003), and serum 
creatinine (rs = 0.588; P = 0.004). 
 
Vital status of dogs with CKD was determined in November 2017.  Median 
follow-up time was 666 days (range, 20-1085 days), during which time six dogs died, 
including two dogs in IRIS stage 2, and four dogs in IRIS stage 3.  No dogs in the 
control group died; no data from this group were included in the survival analysis. 
Causes of death included four dogs with worsening CKD (including one dog that was 
in IRIS stage 2 at the time of recruitment and three dogs that were in IRIS stage 3 at 
the time of recruitment), one dog that died suddenly, and one dog euthanased for a 
bleeding hepatic mass.  Five dogs were either lost to follow up (one dog in IRIS stage 
3) or were still alive (three dogs in IRIS stage 2 and one dog in IRIS stage 3).  Median 
survival time in dogs with CKD was 793 days (95% confidence interval [CI] 141-
NA).  Results of univariate Cox proportional hazards analysis are summarized in 




0.048), serum total protein (P = 0.030), and LVPWDN (P = 0.023).  All three dogs 
with LVPWDN values exceeding the 95% reference value at baseline died during the 
study.  Risk of death increased significantly with decreasing bodyweight (P = 0.035), 
and PCV (P = 0.027).    
 
Discussion 
To the authors’ knowledge, this pilot study is the first to describe 
echocardiographic measurements in dogs with moderate CKD in the context of 
proposed CvRDK.  This condition refers specifically to presence or development of 
heart disease secondarily to CKD, and the current study specifically excluded dogs 
with evidence of primary valvular disease or cardiomyopathy.  Thus, 
echocardiographic measurements in dogs with CKD were compared to age-matched 
healthy controls.  Our analysis found no significant differences at time of enrolment 
in left heart echocardiographic measurements between groups.  These findings differ 
from reports in human patients, wherein chronic renocardiac syndrome in patients 
with advanced, dialysis-dependent CKD is characterized by left ventricular 
hypertrophy, myocardial and arterial fibrosis, and coronary atherosclerosis leading to 
diastolic and systolic dysfunction, heart failure, or sudden death (Herzog et al., 2011; 
Tumlin et al., 2013; Granata et al., 2016).  Echocardiographic changes reported in 
human patients with mild to moderate CKD, similar to the dogs enrolled in the 
present study, include increased left atrial size, increased mitral A wave velocity and 
tissue Doppler imaging changes consistent with diastolic dysfunction (Xhakollari et 
al., 2019); no differences among groups was identified for these variables in the 
present study.  This might be due to the present study being underpowered to detect 




missing, or might reflect true species differences.  Additionally, in human patients, 
systemic hypertension leading to pressure overload is one of the main mechanisms of 
renocardiac syndrome (Tumlin et al., 2013), and another possible explanation for the 
absence of baseline echocardiographic changes in dogs with CKD in the present study 
was that blood pressure measurements were not significantly different from those of 
the control group, despite the finding that 8/11 of the dogs with CKD had elevated 
systolic blood pressures.   
 
However, despite only moderate CKD, over half of the dogs with CKD, 
including 4/7 dogs originally diagnosed as IRIS stage 3, died during the study follow 
up.  The median survival time in the current study (793 days) is similar to previously 
reported cohorts.  In one previous study (Hokamp et al., 2016), dogs with serum 
creatinine of 1.6-2.7 mg/dL had a median survival of approximately 1.5 to 2 years.   
 
A variety of different variables were associated with survival in dogs with 
CKD.  An older age, lighter bodyweight, lower PCV, higher total protein, and thicker 
left ventricular wall thickness were associated with decreased survival. A relationship 
between bodyweight and survival in dogs with CKD has been previously reported, 
with heavier or overweight dogs surviving significantly longer than underweight dogs 
(Parker and Freeman, 2011).  In humans with CKD, the relationship between 
mortality and body mass is complex, and many studies propose a U-shaped curve to 
describe this relationship (Mafra et al., 2008; Lu et al., 2014; Johansen and Lee, 
2015).  Patients that are underweight or severely overweight experience the greatest 
mortality, and patients that are overweight or mildly obese survive the longest, 




wasting and malnutrition (Mafra et al., 2008; Lu et al., 2014; Johansen and Lee, 
2015).   
 
In the present study, dogs with IRIS stage 3 CKD had significantly lower 
PCVs compared with dogs in the control group, consistent with the development of 
mild anemia secondary to CKD. Anemia is associated with progression of CKD in 
cats (Chakrabarti et al., 2012), poor quality of life in dogs (Bartges, 2012), and severe 
anemia increases risk for ventricular hypertrophy, heart failure, and reduced quality of 
life in human CKD patients (Horl, 2013). Although none of the dogs included in the 
study had evidence of clinically-significant anemia that would be expected to 
contribute to left ventricular hypertrophy, it is likely that the influence of PCV on 
survival might be related to dogs with lower PCVs having more advanced disease.  
 
In contrast, there was no difference in serum total protein detected among 
groups, and so this does not appear to be related simply to disease progression.  No 
measurements were outside the laboratory reference interval, suggesting that no dog 
was experiencing clinically-significant dehydration.  However, it is possible that 
subtle dehydration secondary to renal dysfunction might be associated with a poorer 
prognosis – this hypothesis should be tested prospectively. An alternative explanation 
is that feeding of a low protein diet, which has been shown to be associated with 
increased survival times in dogs with CKD, might result in decreased total protein 
measurements.  
 
Left ventricular hypertrophy is an important feature of CKD resulting from 




oxidative stress (Pinheiro da Silva and Vaz da Silva, 2016).  Patterns of left 
ventricular hypertrophy reported in human CKD patients include concentric 
hypertrophy (typically symmetric hypertrophy or asymmetric septal hypertrophy 
(Ghione et al., 1985, Kooman and Leunissen, 1993)), eccentric hypertrophy and 
mixed patterns of hypertrophy (Cusimano et al., 2009). No evidence of concentric 
(either symmetric or asymmetric) or eccentric hypertrophy was found in any of the 
dogs enrolled in the present study, with all measurements of IVSDN, LVPWDN and 
LVIDDN being within the reference intervals. Nevertheless, for each 0.1 unit increase 
in LVPWDN, the risk of mortality increased by 27%, although no association 
between IVSDN and survival was demonstrated. This might suggest that even early, 
subtle increases in left ventricular wall thickness are an indicator of poor prognosis in 
dogs with CKD, even when measurements remain within the reference interval. It is 
noteworthy that this relationship was only demonstrated for LVPWDN, despite the 
typical patterns of left ventricular hypertrophy in human patients being either 
symmetric or involving the septum alone.  Possible explanations for this difference 
include the study being underpowered to demonstrate an association for IVSDN, 
patterns of left ventricular hypertrophy in canine patients differing from those of 
human patients or a spurious association due to an unidentified confounding factor.  
This association should, therefore, be investigated further in a larger population of 
dogs.  
 
One dog in the study died unexpectedly and suddenly, which could have been 
due to a cardiac arrhythmia.  Sudden cardiac death is the most common cause of 




damaged or hypertrophied myocardial substrate, and pro-arrhythmic triggers, such as 
acute fluid shifts and electrolyte imbalances (Poulikakos et al., 2014).   
 
A number of markers previously-shown to be associated with outcome in dogs 
with CKD (e.g. GFR, serum creatinine and SDMA and UPC) were not significant in 
the univariate survival analysis. This is most likely to be because baseline 
measurements were used for the survival analysis, at which point all dogs had 
moderate CKD.  As a result, baseline measurements were similar for all dogs included 
in the analysis and were therefore unlikely to discriminate between survivors and non-
survivors, particularly in a small pilot study. 
 
Our study provides new information involving renal and cardiac biomarkers 
with regards to differences between patient groups, as well as in relation to survival.   
At time of enrolment, dogs with CKD had significantly increased NT-proBNP, 
urinary cystatin B/ creatinine ratio, urinary clusterin/ creatinine ratio and urinary 
NGAL/ creatinine ratio.  Increased NT-proBNP concentration might reflect increased 
production or decreased excretion.  NT-proBNP undergoes renal clearance from the 
circulation, however, the relationship between plasma NT-proBNP and GFR is 
controversial. The observation that plasma NT-proBNP is higher in azotemic dogs 
compared with non-azotemic dogs has long been assumed to represent accumulation 
due to decreased GFR (Raffan et al., 2009), however, a previous study showed that 
GFR was not an independent predictor of plasma NT-proBNP concentration 
(Pelander et al., 2017).  In the current study plasma NT-proBNP was only moderately 
correlated with GFR, suggesting other factors probably contribute to increased plasma 




increase in production, for instance, in response to increased cardiac filling pressures 
or neurohormonal activation.  In addition to NT-proBNP, three separate markers of 
active kidney injury, urinary cystatin B, clusterin and NGAL, were increased in dogs 
with CKD.  Cystatin B is a protein inhibitor of cysteine proteases, whereas NGAL is a 
protein that binds iron-containing ligands (Steinbach et al., 2014).  Serum NGAL is 
increased in dogs with congestive heart failure, consistent with CvRDH (Jung et al., 
2018).  Clusterin is a di-sulfide-linked glycoprotein that has protective, anti-apoptotic, 
and anti-fibrotic properties (Jung et al., 2012), and is upregulated in response to 
tubular epithelial injury in dogs (Garcia-Martinez et al., 2012; Yerramilli et al., 2016).  
All three are found in renal tubular cells, and detection in the blood or urine is 
probably associated with active tubular injury or necrosis that has caused rupture of 
renal tubular epithelial cells. Increased concentrations of protective proteins such as 
clusterin and NT-proBNP might be a marker of disease severity, signal inadequate 
biological efficacy, or altered catabolism or excretion.     
 
The current pilot study has a number of limitations.  Standard 
echocardiography was performed, and detection of subtle differences in cardiac 
structure or function might require more sensitive ultrasound techniques, or 
alternative techniques such as MRI or cardiac catheterization.  Dogs with advanced 
CKD, or those with uncontrolled systemic hypertension, were not examined.  The 
study population was small, which prevents the ability to perform multivariable 
survival analysis.  Variables identified as being associated with survival should 






In this study, dogs with moderate CKD demonstrated increased markers of 
cardiac stress and kidney injury compared to age-matched controls.  While there was 
no significant difference in echocardiographic measurements between CKD and 
healthy controls, LVPWDN was associated with worse survival in dogs with CKD.  
These data help provide insight into the proposed phenomenon of CvRDK, provide 
information regarding baseline heart measurements in dogs with moderate CKD, and 
are amongst the first to investigate an association between echocardiographic indices 
and mortality in dogs with CKD. 
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Table 1 1 




(n = 12) 
IRIS Stage 2  
(n = 5) 
IRIS Stage 3  
(n = 6, unless 
otherwise specified) 
P (overall groupwise 
comparison) 
Post hoc groupwise 
comparisons where P<0.05 
Age (years) N/A 9.0 (2.6 – 14.1) 8.0 (3.3 – 15.6) 9.6 (1.2 – 12.5) 0.922 N/A 
Bodyweight (kg) N/A 21.9 (11.6 – 30.9) 33.3 (10.0 – 38.5) 27.4 (11.2 – 42.4) 0.433 N/A 
Heart rate (bpm) 60-180 123 (90 – 150) 108 (100 – 120) 112 (80 – 130) 0.078 N/A 
Systolic blood pressure 
(mmHg) 
110-160 140.5 (110.0 – 178.0) 170.0 (128.0 – 184.0) 173.0 (130.0 – 210.0) 0.090 N/A 
Packed cell volume (%) 41-58 49.0 (42.0 – 54.0) 49.0 (38.0 – 53.0) 38.0 (33.0 – 44.0) 
(n = 5) 
0.013 a  Control vs. IRIS 3, P=0.017 
Serum total protein 
(g/dL) 
5.0-8.0 6.5 (6.0 – 7.8) 7.0 (6.2 – 7.9) 6.8 (6.0 – 8.0) 0.363 N/A 
BUN (mg/dL) 5-30 14 (9 – 22) 20 (16 – 37) 27 (18 – 81) 0.002 a  Control vs. IRIS 3, 
P=0.003 
Creatinine (mg/dL) 0.7-1.8 1.0 (0.8 – 1.5) 1.7 (1.4 – 1.9) 2.4 (2.3 – 3.1) 0.0001 a  Control vs. IRIS 3, 
P=0.0001 
Phosphorus (mg/dL) 2.8-6.1 3.9 (3.0 – 5.3) 4.0 (3.3 – 4.8) 4.6 (3.3 – 6.8) 0.392 N/A 
Na+ (mmol/L) 140-150 146.5 (142.0 – 151.0) 143.0 (139.0 – 147.0) 142.5 (139.0 – 145.0) 0.011 a  Control vs. IRIS 3, 
P=0.012 
K+ (mmol/L) 4.0-5.2 4.6 
(4.0 – 5.0) 
4.7 
(4.2 – 5.2) 
4.7 
(4.4 – 5.9) 
0.353 N/A 
USG >1.025 1.036 
(1.010 – 1.061) 
1.010 
(1.008 – 1.018) 
1.010 
(1.002 – 1.016) 
0.001 a Control vs. IRIS 2, 
P=0.025; Control vs. 
IRIS 3, P=0.003 
UPC <0.50 0.02 
(0.01 – 0.15) 
0.09 
(0.08 – 1.82) 
0.60 
(0.10 – 5.33) 
0.001 a  Control vs. IRIS 2; 
P=0.048, Control vs. 





BUN; blood urea nitrogen, Na+; sodium, K+; potassium, USG; urinary specific gravity, UPC; urinary protein to creatinine ratio. 4 




Table 2 6 




(n = 12, unless 
otherwise specified) 
IRIS Stage 2 
(n = 5) 
IRIS Stage 3 






Post hoc groupwise 
comparisons where P<0.05 
GFR (mL/ min/ kg) 
 
Expected 
mean = 5.48 
2.33 (1.71 – 4.33) 
(n=11) 
1.20 (1.05 – 1.49) 0.76 (0.55 - 1.04) <0.0001 a 
 
Control vs. IRIS 2, P=0.050; 




(8.0 – 14.0) 
16.0 
(14.0 – 25.0) 
24.0 
(16.0 – 30.0) 
<0.0001 a  Control vs. IRIS 2, P=0.028; 
Control vs. IRIS 3, P<0.001; 




(250 – 1433) 
604 
(306 – 1567) 
1788 
(1295 – 2881) 
(n=5) 




(0.00 – 0.08) 
0.01 
(0.00 – 0.12) 
0.04 
(0.00 – 0.05) 
0.830 N/A 
Plasma cystatin B 
(ng/mL) 
N/A 199.0 (109.0 – 
325.0) 
239.0 (174.0 – 311.0) 218.5 (150.0 – 260.0) 0.599 N/A 





(0.00 – 1.95) 
7.03 
(0.00 – 14.87) 
5.70 




Control vs. IRIS 2, P=0.077, 





(0.07 – 8.63) 
2.05 
(0.47 – 6.69) 
4.05 
(2.94 – 13.74) 
(n = 4) 





(0.00 – 0.06) 
0.28 
(0.00 – 0.47) 
0.57 
(0.05 – 0.81) 
(n = 4) 
<0.001 a Control vs. IRIS 2, P=0.072, 




IVSDN (cm/[kg.241]) 0.29 – 0.59 0.44 (0.37 - 0.50) 0.50 (0.38 - 0.54) 0.50 (0.33 - 0.57) 0.125 N/A 
LVPWDN 
(cm/[kg.232]) 
0.29 - 0.60 0.44 (0.36 - 0.59) 0.51 (0.42 - 0.59) 0.50 (0.43 - 0.59) 0.284 N/A 
LVIDDN 
(cm/[kg.294]) 
1.27 - 1.85 1.50 (1.30 – 1.60) 1.30 (1.20 – 1.50) 1.60 (1.30 – 1.60) 0.096 N/A 
LVIDSN 
(cm/[kg.315])  
0.71 – 1.26 0.91 (0.79 – 1.10) 0.79 (0.63 - 0.96) 0.87 (0.78 – 1.00) 0.257 N/A 
Fractional shortening 
(%) 
20 - 55 32.7 (20.2 – 39.4) 35.9 (25.0 – 43.0) 35.3 (29.6 – 67.8) 0.305 N/A 
LA:Ao <1.6 1.20 
(0.91 – 1.40) 
1.20 
(0.95 – 1.30) 
1.15 
(0.93 – 1.40) 
0.946 N/A 
Mitral E wave 
velocity (m/s) 
0.48 – 1.08 0.67 (0.40 - 0.95) 0.67 (0.48 - 0.86) 0.83 (0.58 – 1.14) 0.106 N/A 
Mitral A wave 
velocity (m/s) 
0.30 - 0.80 0.63 (0.44 - 0.94) 0.66 (0.56 - 0.88) 0.71 (0.57 - 1.01) 0.352 N/A 
Mitral EA ratio 1 - 2 1.06 (0.65-1.63) 0.80 (0.72-1.29) 1.03 (0.66-1.64) 0.768 N/A 
Mitral E’wave 
velocity (cm/s) 
3.7 - 17.1 8 (14 – 12) 6 (5 – 7) 
(n = 3) 
6 (5 – 8) 
(n = 3) 
0.153 N/A 
Mitral E/E’ ratio 
(m/cm) 
10.9 ± 3.3 8.0 (4.0 – 17.0) 11.0 (7.0 – 15.0) 
(n = 3) 
15.0 (10.0 – 17.0) 
(n = 3) 
0.090 N/A 
 8 
GFR; glomerular filtration rate, SDMA; symmetric dimethylarginine, NGAL; neutrophil gelatinase-associated lipocalin, NT-proBNP; N-9 
terminal pro-B-type natriuretic peptide, cTnI; cardiac troponin I, IVSDN; interventricular septal wall thickness in diastole, normalized for 10 
bodyweight, LVPWDN; left ventricular posterior wall thickness in diastole, normalized for bodyweight, LVIDDN; left ventricular internal 11 
dimension in diastole, normalized for bodyweight, LVIDSN; left ventricular internal dimension in systole, normalized for bodyweight, LA:Ao; 12 
left atrial to aortic root ratio; N/A, not available. 13 
a P<0.05  14 




Table 3  16 
Univariate Cox proportional hazards analysis of factors associated with all-cause mortality at enrolment into the study.  17 
 Hazard ratio (HR) 95% confidence interval for HR P 
Age (years) 1.330 1.002 - 1.764 0.048 a 
Bodyweight (kg) 0.891 0.801 - 0.992 0.035 a 
Heart rate (bpm) 1.083 0.988 - 1.187 0.090 
Systolic blood pressure (mmHg) 1.013 0.976 - 1.051 0.509 
Packed cell volume (%) (n=10) 0.745 0.575 - 0.967 0.027 a 
Serum total protein (.1 g/dL) 1.458 1.037 - 2.049 0.030 a 
GFR (mL/min/kg) 0.248 0.013 - 4.771 0.356 
UPC (mg/g) 1.520 0.741 - 3.121 0.254 
BUN (mg/dL) 1.154 0.983 - 1.354 0.079 
Creatinine (mg/dL) 2.801 0.615 - 12.750 0.183 
Phosphorus (mg/dL) 1.848 0.909 - 3.759 0.090 
SDMA (mg/dL) 1.036 0.900 - 1.192 0.626 
NT-proBNP (100 pmol/L) (n=10) 1.020 0.916 - 1.136 0.717 
cTnI x (.01 ng/mL) 0.957 0.705 -1 .298 0.777 
Plasma cystatin B (10ng/mL) (n=10) 1.030 0.857 - 1.238 0.751 
Urinary cystatin B/ creatinine ratio (1ng/mg) (n = 9) 
 
1.167 0.954 - 1.427 0.133 
Urinary clusterin/ creatinine ratio (1ng/mg) (n = 9) 
 
1.526 0.948 - 2.454 0.082 
Urinary NGAL/ creatinine ratio (1ng/mg) (n = 9) 
 
27.353 0.637 - 1175.308 0.085 
IVSDN (0.1 unit)  1.122 0.954 - 1.319 0.163 




LVIDDN (0.1 unit) 0.997 0.939 - 1.058 0.920 
LVIDSN (0.1 unit)  0.965 0.906 - 1.029 0.275 
LA:Ao (0.1 unit) 0.773 0.467 - 1.279 0.316 
Mitral E wave velocity (0.1 m/s) 0.782 0.458 - 1.334 0.367 
Mitral EA ratio (0.1 units) 0.793 0.580 - 1.084 0.146 
Mitral E’wave velocity (cm/s) 0.965 0.371 - 2.513 0.942 
Mitral E/E’ ratio (m/cm) 0.488 0.000 – 2.670E13 0.965 
 18 
BUN; blood urea nitrogen, Na+; sodium, K+; potassium, USG; urinary specific gravity, UPC; urinary protein to creatinine ratio, GFR; glomerular 19 
filtration rate, SDMA; symmetric dimethylarginine, NGAL; neutrophil gelatinase-associated lipocalin, NT-proBNP; N-terminal pro-B-type 20 
natriuretic peptide, cTnI; cardiac troponin I, IVSDN; interventricular septal wall thickness in diastole, normalized for bodyweight, LVPWDN; 21 
left ventricular posterior wall thickness in diastole, normalized for bodyweight, LVIDDN; left ventricular internal dimension in diastole, 22 
normalized for bodyweight, LVIDSN; left ventricular internal dimension in systole, normalized for bodyweight, LA:Ao; left atrial to aortic root 23 
ratio. 24 
a P<0.05 25 
